Parkinson’s Disease

Parkinson’s is characterized by loss of dopaminergic neurons in the substantia nigra. The dopaminergic neurons are characterized by two types of activity- Phasic firing and continuous tonic firing. The conventional Anti-parkinson’s treatment  induce only  phasic firing  without the continuous tonic firing seen in normal physiologic conditions. This results in motor fluctuations. It is  because of the short term effects of the existing drugs. Continuous delivery of drugs in a controlled and continuous manner can effect tonic firing of the dopaminergic neurons. The existing techniques like CED and cerebro-ventricular infusions involve surgical manipulations in the brain. This makes the brain prone to infection from external sources.

Our patented technique and device helps in controlled and continuous delivery of drugs into the brain from the maxillo-facial region thereby avoiding the major surgical interventions currently performed in the brain and duodenum. In vivo proof of concept studies in rabbit models have been successful for dopamine.

Alzheimer’s Disease

Alzheimer’s is characterized by deposition of Aβ and Tau in the brain. Active and passive immunization techniques have been tried in the last years. But the treatments have not been successful because of the blood brain barrier which prevents the entry of large antibodies into the brain. Only 0.1% of the antibodies given intravenously enters the brain and the size is limited to 0.5 kda. Moreover higher concentrations have also resulted in ARIA in many patients.

Our patented technique and device helps in controlled and continuous delivery of antibodies of even 50 Kda into the brain from the maxillo-facial region .Very low doses of antibody could be given. Ex vivo proof of concept studies in goat-head models have been successful for Anti-Gfap.

Brain Cancers: